PILRA

PILRA (FDF03) is a myeloid inhibitory immunoreceptor that dampens activating signaling and, in microglia, gates the immunometabolic response to ApoE4 (PMID:10903717, PMID:41337541). It carries cytoplasmic ITIM-like sequences that become tyrosine-phosphorylated upon receptor engagement and recruit the SH2-domain phosphatases SHP-2 and, to a lesser extent, SHP-1 (PMID:10903717); through this inhibitory module, PILRA cross-linking suppresses calcium mobilization downstream of CD32/FcγRII aggregation, while leaving GM-CSF-driven monocyte-to-dendritic-cell differentiation intact, marking a context-specific inhibitory output (PMID:10903717). In human iPSC-derived microglia, loss of PILRA reverses ApoE4-driven deficits—restoring lipid storage and protecting against lipotoxicity, improving mitochondrial bioenergetics and antioxidant capacity, enhancing chemotaxis, and lowering inflammation—through PPAR and STAT1/3 signaling (PMID:41337541); transplantation of PILRA-knockout human microglia into AD mice reduces amyloid pathology and rescues synaptic markers, and a ligand-blocking antibody phenocopies the knockout, establishing PILRA as pharmacologically tractable (PMID:41337541). A synonymous PILRA variant (rs2405442:T>C) disrupts a 5' ramp of slowly translated codons and lowers both mRNA and protein levels (PMID:40149715).

1. 2000 Medium

   Established the molecular basis for PILRA inhibitory signaling by showing it is an ITIM-bearing receptor that recruits tyrosine phosphatases, defining its signaling module.

   Evidence Overexpression in pervanadate-treated U937 cells with phosphorylation and SHP-1/SHP-2 recruitment assays

   PMID:10903717

   Open questions at the time

   • Physiological ligand and activating stimulus not identified in this assay
   • Relative contribution of SHP-1 vs SHP-2 to downstream effects not resolved
   • Pervanadate is a non-physiological phosphatase inhibitor, not a receptor-engagement context
2. 2000 Medium

   Demonstrated that PILRA functions as a bona fide inhibitory receptor by suppressing activating-receptor calcium signaling, and defined the specificity of that inhibition.

   Evidence Receptor cross-linking with calcium mobilization assay against CD32/FcγRII aggregation, plus a negative GM-CSF differentiation assay, in transfected U937 cells

   PMID:10903717

   Open questions at the time

   • Which endogenous activating pathways PILRA naturally counter-regulates is unknown
   • Mechanism distinguishing inhibited (calcium) from non-inhibited (differentiation) outputs not defined
   • Single cell line, artificial cross-linking rather than ligand engagement
3. 2025 High

   Connected PILRA inhibitory function to disease-relevant microglial biology by showing knockout rescues ApoE4-driven immunometabolic deficits through defined downstream pathways.

   Evidence CRISPR knockout in iPSC-derived microglia with pharmacological PPAR and STAT1/3 inhibitor studies and lipid, mitochondrial, chemotaxis, and inflammation assays

   PMID:41337541

   Open questions at the time

   • How ITIM/SHP signaling mechanistically links to PPAR and STAT1/3 outputs is not delineated
   • Whether PILRA acts cell-autonomously via its known phosphatase module or through a distinct route is unresolved
   • The ApoE4 ligand or stimulus engaging PILRA in microglia is not defined
4. 2025 High

   Validated PILRA as a therapeutic target in vivo and showed it is druggable by antibody blockade.

   Evidence Chimeric AD mouse transplanted with human PILRA KO iPSC-microglia, plus ligand-blocking antibody phenocopy in iMG

   PMID:41337541

   Open questions at the time

   • Long-term and dose effects of antibody blockade not assessed
   • Identity of the blocked ligand not specified
   • Single-study in vivo evidence
5. 2025 Medium

   Provided a mechanistic explanation for how a synonymous PILRA variant alters expression, linking genetic variation to receptor dosage.

   Evidence qPCR and ELISA of wildtype vs mutant PILRA constructs in CHO cells

   PMID:40149715

   Open questions at the time

   • Single-lab cell-based assay without independent replication
   • Effect on endogenous human myeloid/microglial PILRA expression not tested
   • Link between variant and the microglial/AD phenotypes not directly demonstrated

• The endogenous PILRA ligand engaged in microglia and the mechanistic bridge from its ITIM/SHP signaling to PPAR and STAT1/3 metabolic reprogramming remain undefined.
• No identified physiological ligand in the microglial context
• No mechanistic chain connecting SHP recruitment to transcriptional/metabolic outputs
• No structural model of PILRA-ligand engagement in the corpus